Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26289025 | 0.94 | LIMK1 (0.41) | LIMK1APPG6PDXDHSLC22A12 | |
| SCHEMBL25544860 | 0.93 | LIMK1 (0.47) | LIMK1APPG6PDMMP3HRH3 | |
| SCHEMBL25544991 | 0.93 | LIMK1 (0.47) | LIMK1APPG6PDMMP3HRH3 | |
| SCHEMBL25545000 | 0.90 | LIMK1 (0.48) | LIMK1APPG6PDMMP3HRH3 | |
| SCHEMBL25544986 | 0.89 | LIMK1 (0.41) | LIMK1APPG6PDXDHSLC22A12 | |
| SCHEMBL25544852 | 0.89 | LIMK1 (0.41) | LIMK1APPG6PD | |
| SCHEMBL25544998 | 0.86 | LIMK1 (0.40) | LIMK1APPG6PD | |
| SCHEMBL26289003 | 0.85 | LIMK1 (0.39) | LIMK1APPG6PDHRH3 | |
| SCHEMBL25544848 | 0.82 | APP (0.38) | LIMK1APPG6PDMIF | |
| SCHEMBL25544842 | 0.82 | APP (0.40) | LIMK1APPG6PDMIFESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4183784-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | Lapto Co., Ltd. (KR) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAT1, FTO, SETDB1 | LIMK1 116/4885APP 2445/4885G6PD 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.